SILO PHARMA, INC. Amortization of Intangible Assets
SILO PHARMA, INC. (SILO) reported Amortization of Intangible Assets of $5.88 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-13
- SILO PHARMA, INC. amortization of intangible assets for the quarter ending 2026-06-30 was $2.94K, a 18.80% increase year-over-year.
- SILO PHARMA, INC. amortization of intangible assets for the quarter ending 2026-03-31 was $2.94K, a 5.01% decline year-over-year.
- SILO PHARMA, INC. amortization of intangible assets for the quarter ending 2025-12-31 was $2.94K, a 52.51% decline year-over-year.
- SILO PHARMA, INC. amortization of intangible assets for the quarter ending 2025-09-30 was $2.94K.
- SILO PHARMA, INC. amortization of intangible assets for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- SILO PHARMA, INC. amortization of intangible assets for fiscal 2018 was $17.55K.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.94K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $5.88K 10-Q · filed 2026-08-13 | $8.81K derived: sum of 3 quarters · filed 2026-08-13 | $11.75K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $2.94K 10-Q · filed 2026-05-14 | $5.87K derived: sum of 2 quarters · filed 2026-05-14 | $8.81K derived: sum of 3 quarters · filed 2026-05-14 | $11.29K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $2.94K derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-14 | $5.88K derived: sum of 2 quarters · filed 2026-04-14 | $8.35K derived: sum of 3 quarters · filed 2026-08-13 | $11.44K POS AM · filed 2026-04-14 |
| 2025-09-30 | $2.94K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $5.41K derived: sum of 2 quarters · filed 2026-08-13 | $8.50K 10-Q · filed 2025-11-13 | $14.69K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $2.47K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $5.57K 10-Q · filed 2026-08-13 | $11.75K derived: sum of 3 quarters · filed 2026-08-13 | $11.75K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $3.09K 10-Q · filed 2026-05-14 | $9.28K derived: sum of 2 quarters · filed 2026-05-14 | $9.28K derived: sum of 3 quarters · filed 2026-05-14 | |
| 2024-12-31 | $6.18K derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-14 | $6.18K derived: sum of 2 quarters · filed 2026-04-14 | $6.18K POS AM · filed 2026-04-14 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-13 | |||
| 2019-12-31 | $0.00 10-K · filed 2020-03-20 | |||
| 2018-12-31 | $17.55K 10-K · filed 2020-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |